OBJECTIVE: To investigate the impact of variant histologies of urothelial carcinoma of the bladder (UCB) on oncologic outcomes after radical cystectomy (RC). MATERIALS AND METHODS: Data from 1984 UCB patients treated by RC without preoperative chemo- or radiotherapy were reviewed for histological differentiation and variants. We analysed the differences between pure UCB and UCB with variant histology, and those between the different histological variants using various stratifications. RESULTS: Overall, 488 (24.6%) patients had UCB variants with squamous cell (11.4%) and glandular differentiation (3.8%) being the most common. Histological UCB variants were associated with advanced tumour stage, lymphovascular invasion and lymph node metastasis (all p-values<0.01) when compared to pure UCB. In univariable analyses, patients with non-squamous UCB variants were at significantly higher risk for disease recurrence and cancer-specific mortality than those with pure UCB patients (p-values=0.001) and those with squamous cell differentiated UCB (p-values=0.04); the latter two had the same risk. In multivariable analyses that adjusted for the effects of standard clinicopathologic characteristics, variant UCB histology was not associated with both survival end-points. In patients treated with adjuvant chemotherapy (n=492) there was no difference in cancer-specific survival between pure UCB, squamous cell differentiated UCB and other histological UCB variants. CONCLUSIONS: A quarter of UCB patients treated with RC harboured histological UCB variants. Variant UCB histologies were associated with features of biologically aggressive disease. While variant UCB histology was associated with worse outcomes in univariable analyses, this effect did not remain significant in multivariable analyses.
OBJECTIVE: To investigate the impact of variant histologies of urothelial carcinoma of the bladder (UCB) on oncologic outcomes after radical cystectomy (RC). MATERIALS AND METHODS: Data from 1984 UCB patients treated by RC without preoperative chemo- or radiotherapy were reviewed for histological differentiation and variants. We analysed the differences between pure UCB and UCB with variant histology, and those between the different histological variants using various stratifications. RESULTS: Overall, 488 (24.6%) patients had UCB variants with squamous cell (11.4%) and glandular differentiation (3.8%) being the most common. Histological UCB variants were associated with advanced tumour stage, lymphovascular invasion and lymph node metastasis (all p-values<0.01) when compared to pure UCB. In univariable analyses, patients with non-squamous UCB variants were at significantly higher risk for disease recurrence and cancer-specific mortality than those with pure UCB patients (p-values=0.001) and those with squamous cell differentiated UCB (p-values=0.04); the latter two had the same risk. In multivariable analyses that adjusted for the effects of standard clinicopathologic characteristics, variant UCB histology was not associated with both survival end-points. In patients treated with adjuvant chemotherapy (n=492) there was no difference in cancer-specific survival between pure UCB, squamous cell differentiated UCB and other histological UCB variants. CONCLUSIONS: A quarter of UCB patients treated with RC harboured histological UCB variants. Variant UCB histologies were associated with features of biologically aggressive disease. While variant UCB histology was associated with worse outcomes in univariable analyses, this effect did not remain significant in multivariable analyses.
Authors: Francesco Soria; Marco Moschini; Andrea Haitel; Gregory J Wirth; Jose A Karam; Christopher G Wood; Morgan Rouprêt; Vitaly Margulis; Pierre I Karakiewicz; Alberto Briganti; Jay D Raman; Solene-Florence Kammerer-Jacquet; Romain Mathieu; Karim Bensalah; Yair Lotan; Mehmet Özsoy; Mesut Remzi; Kilian M Gust; Shahrokh F Shariat Journal: World J Urol Date: 2016-06-07 Impact factor: 4.226
Authors: Stefania Zamboni; Luca Afferi; Francesco Soria; Atiqullah Aziz; Mohammad Abufaraj; Cedric Poyet; Andrea Necchi; David D'Andrea; Giuseppe Simone; Mariaconsiglia Ferriero; Ettore Di Trapani; Claudio Simeone; Alessandro Antonelli; Andrea Gallina; Francesco Montorsi; Alberto Briganti; Renzo Colombo; Giorgio Gandaglia; Agostino Mattei; Philipp Baumeister; Livio Mordasini; Kees Hendricksen; Charlotte S Voskuilen; Michael Rink; Shahrokh F Shariat; Evanguelous Xylinas; Marco Moschini Journal: World J Urol Date: 2020-07-25 Impact factor: 4.226
Authors: Qiang Li; Melissa Assel; Nicole E Benfante; Eugene J Pietzak; Harry W Herr; Machele Donat; Eugene K Cha; Timothy F Donahue; Bernard H Bochner; Guido Dalbagni Journal: Eur Urol Focus Date: 2017-06-27
Authors: Mohammad Abufaraj; Shahrokh F Shariat; Beat Foerster; Carmen Pozo; Marco Moschini; David D'Andrea; Romain Mathieu; Martin Susani; Anna K Czech; Pierre I Karakiewicz; Veronika Seebacher Journal: World J Urol Date: 2017-11-11 Impact factor: 4.226
Authors: Alexandra Masson-Lecomte; Evanguelos Xylinas; Morgane Bouquot; Mathilde Sibony; Yves Allory; Eva Comperat; Marc Zerbib; Alexandre de la Taille; Morgan Rouprêt Journal: World J Urol Date: 2014-09-02 Impact factor: 4.226
Authors: Jeremy W Martin; Simone L Vernez; Yair Lotan; Ahmed Abdelhalim; Rahul Dutta; Ahmed Shokeir; Hassan Abol-Enein; Ahmed Mosbah; Mohamed Ghoneim; Ramy F Youssef Journal: World J Urol Date: 2018-05-14 Impact factor: 4.226
Authors: Richard Naspro; Marco Finati; Marco Roscigno; Federico Pellucchi; Giovanni La Croce; Mario Sodano; Michele Manica; Daniela Chinaglia; Luigi F Da Pozzo Journal: World J Urol Date: 2020-07-21 Impact factor: 4.226
Authors: Marco Moschini; David D'Andrea; Stephan Korn; Yasin Irmak; Francesco Soria; Eva Compérat; Shahrokh F Shariat Journal: Nat Rev Urol Date: 2017-09-12 Impact factor: 14.432